Replies to post #310202 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yes, which is another very good reason SAS Cat B prescriptions will be limited exactly as per the Anavex PR as opposed to all the persistent silly revenue speculation.

[Steady_T]

And if there are no SAEs to report then it is not an issue. Since the folks that are taking 2-73 have been taking it for 5 years it seems that the chances of an SAE are pretty low at this point.

Your argument about not expanding the SAS Cat B population makes a lot of sense. There doesn't seem to be much upside for the company and a significant possible downside.

Thanks for that info.